Health Economics›Renal cell carcinoma›Metastatic disease first-line

Metastatic disease first-line

Renal cell carcinoma · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Atezolizumab and Bevacizumab Variant #01	—	R 59 878	21d	11.2 mo	—	17	R 1 017 923 PFS proxy	1
Sorafenib monotherapy Variant #04	—	R 37 339	28d	~3.9 mo	—	~5	~R 186 694 PFS proxy · indirect	1
Sunitinib monotherapy Variant #05	—	R 33 433	28d	9.2 mo	—	11	R 367 764 PFS proxy	2
Everolimus monotherapy Variant #01	—	R 18 360	28d	7.9 mo	—	9	R 165 237 PFS proxy	1
Gemcitabine and Sunitinib Variant #01	—	R 10 776	21d	—	—	—	—	—
Medroxyprogesterone acetate monotherapy Variant #01	—	R 1 178	28d	—	6.0 mo	—	—	1
Vinblastine monotherapy Variant #01	—	R 196	14d	—	—	—	—	—
High-dose Interleukin-2 N/A - secondary systemic drug	—	R 43	28d	—	—	—	—	—
Temsirolimus monotherapy N/A - secondary systemic drug	—	R 0	28d	—	10.9 mo	—	—	1
Interferon alfa-2a and Interleukin-2 Variant #01 Partial	—	—	90d	—	22.8 mo	—	—	1
Interferon alfa-2a monotherapy Variant #01 Partial	—	—	7d	—	13.0 mo	—	—	4
Interferon alfa-2b monotherapy Variant #01 Partial	—	—	28d	~13.2 mo	—	~15	—	2
Low-dose Interleukin-2 Variant #01 Partial	—	—	42d	—	—	—	—	—
Placebo Partial	—	—	—	—	—	—	—	1

14 of 14 regimens shown